Sign In  |  Register  |  About Burlingame  |  Contact Us

Burlingame, CA
September 01, 2020 10:18am
7-Day Forecast | Traffic
  • Search Hotels in Burlingame

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:

Angel Pharma to Start China Trial of ITK Inhibitor for Lymphoma

Angel Pharma, a Jiaxing- Los Angeles company, was approved to start China clinical trials of a small molecule ITK inhibitor in patients with relapsed/refractory T-cell lymphomas. CPI-818, the first ITK inhibitor in clinical development, is designed to selectively inhibit ITK (interleukin-2-inducible T-cell kinase) without affecting related kinases such as RLK and BTK. Corvus Pharma discovered the drug. One year ago, Corvus formed Angel as a China JV with $106 million in original capital and China rights to three of its assets, including CPI-818.  More details.... Stock Symbol: (NSDQ: CRVS) Share this with colleagues: // //
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
Copyright © 2010-2020 Burlingame.com & California Media Partners, LLC. All rights reserved.